

RESPOND

International Cohort Consortium
of Infectious Diseases

A simple tool to evaluate the effectiveness of HIV care for settings with gaps in data availability

Amanda Mocroft, University College London, UK

for *Dorthe Raben*, J Trajanovska, J Kowalska, A Vassilenko, N Chkhartishvili, S Dragas, A Harxhi, GJ Dragovic, H Garges, J Gallant, J Lundgren, A Phillips, A Pharris, Y Yazdanpanah, ML Jakobsen, A Mocroft and the International Cohort Consortium of Infectious Diseases RESPOND


Presenter Disclosure Information

Amanda Mocroft

**Honoraria and consultancy fees from Gilead,
ViiV and A. Craig Eiland**

Background

- The continuum of care (or the 90-90-90 goals) can help identify strengths or weaknesses in the ability to diagnose and link people with HIV to care and monitor treatment programs
- Data on people on ART and with viral suppression (VS) rely on good clinical data and reporting mechanisms between national surveillance institutions and clinical cohorts that are not in place in all countries across Europe
- Many HIV clinics do not have the IT infrastructure or resources to routinely report information on all patients in care



Objectives

- To investigate data required to estimate the ‘right-hand side’ of the HIV continuum in a clinic setting by using different sampling techniques and random samples from participating clinics
- To develop a simple accessible online tool to enable clinics to calculate aggregated prevalence estimates for people on ART and with VS

Methods


- Data collected on all with HIV seen ≥ 1 during 2017 at 7 clinics participating in RESPOND
- The % on ART and VS (VL < 200 copies/ml [< 500 copies/ml in Belarus]) calculated using the total number under care in the clinic as the denominator
- Persons with missing VL assumed to be not VS

Note

*Analyses focus on ‘**clinic specific 2nd 90**’ - % seen in clinic who are still under FU and on ART (excluding drop-outs included in UNAIDS 90-90-90).*

Results

Clinics participating in study : N=8852




- 93.8% on ART (95% CI 93.3–94.2)
- 76.7% were VS* (95% CI 75.8–77.6%)


All	N=8852	N	%
Age	<=30	1255	14.2
	30-40	3046	34.4
	>40	4550	51.4
	Missing	1	0.0
Last CD4	<=500	3833	43.3
	>500	4900	55.4
	Missing	119	1.3
Gender / risk	MSM	3157	35.7
	M heterosexual	1470	16.6
	F heterosexual	1544	17.4
	M IDU	1648	18.6
	F IDU	197	2.2
	M Other	669	7.6
	F Other	165	1.9
Years since HIV+	<=1	1180	13.3
	1-3	1922	21.7
	>3	5719	64.6
	Unknown	31	0.4

*people without VL data were assumed to be unsuppressed

Continuum of care 2017 (at last visit)




Continuum of Care - showing missing VL



Sampling methods: Why chose a sample?

- Most clinics have limited resources and many individuals under follow-up
- Practically not realistic to input complete clinic population into online tool to get continuum (approx. 10-15 mins per individual)
- Interested in required sample size needed from clinic to reliably estimate continuum for whole of clinic population

Continuum of care 2017 (at last visit)



Sampling methods: How to choose a sample?


Possible methods:

1. Different random samples (ie 5%, born in January)
2. Bootstrapping techniques¹ using 500 or 1000 repetitions to identify 2.5 and 97.5 percentiles for the percentage on ART/VS
3. Application of WHO HIV drug resistance (HIVDR) Early Warning Indicators (EWI) – sampling²


¹Bootstrapping is a resampling technique used to obtain estimates of summary statistics using random sampling with replacement

²WHO consolidated guidelines on person-centred HIV patient monitoring and vasa surveillance annex 2.4.6


1. Different random samples in one center



2. Bootstrapping



A: sample size 50; 1,000 repetitions



B: sample size 100; 1,000 repetitions

—|—| 2.5 and 97.5 percentiles from bootstrapping samples

3. Random sampling

- Sample sizes calculated to achieve 95% confidence intervals of +7% for clinic specific results assuming 81% on ART are VS¹

Annual number of patients in clinic	Number to be sampled	Estimated hours work (10-15 mins per patient)
1500-9000	115-120	20 - 30
450-1500	100-115	16.7 - 28.75
200	75	12.5 - 18.75
100	55	9.2 - 13.75
50	35	5.8 - 8.75

¹WHO consolidated guidelines on person-centred HIV patient monitoring and vire surveillance annex 2.4.6

Functions of the tool

1. Calculator to define required sample size
2. Importance and directions for ensuring random selection of patients
3. Patient data entry form with core data items¹
4. Outcome: user friendly aggregate data presenting % on ART and VL suppressed – in excel, pdf, ppt etc

¹At last visit : on ART, VL, gender, HIV exposure, CD4, (race)

Conclusions

- 7 clinics in RESPOND provided data for testing ‘proof of concept’ and constructing the RHS of the continuum
- Different sampling techniques investigated for impact on estimates of the clinic continuum
- We propose random sample based on statistical formula¹ with sample required dependent on clinic size and precision of required estimate
- Development and validation of tool as next stage

The tool will support clinics to estimate clinic specific % on ART and VS for:

- Quality control/benchmarking (self-applied auditing tool)
- Support surveillance data in countries with fragmented data on VS (reporting purposes)

If interested in taking part in the development, testing and use of the tool, please contact:

respond.rigshospitalet@regionh.dk or
dorthe.raben@regionh.dk

ACKNOWLEDGEMENTS



Cohort principal investigators:

De Wit (St. Pierre, Brussels), R. Zangerle (AHICOS), M. Law (AHOD), F. Wit (ATHENA) G. Wandeler (EuroSIDA), C. Stephan (Frankfurt), N. Chkhartishvili (IDACIRC), C. Pradier (Nice HIV cohort), A. d'Arminio Monforte (ICoNA), C. Mussini (Modena), J. Casabona & J.M. Miro (PISCIS), H. Günthard (SHCS), A. Sönnnerborg (Swedish InfCare), C. Smith (Royal Free HIV cohort), A. Castagna (St. Rafael, Milano), J.C. Wasmuth (Bonn, HIV Cohort) and J.J. Vehreschild (Cologne, HIV cohort).

Cohort Coordinator, operational team members and data management:

C. Necsoi, M. Delforge (st. Pierre, Brussels), H. Appoyer, U. Dadogan, G. Leierer (AHIVCOS), J. Hutchinson, R. Pühr (AHOD), P. Reiss, M. Hillebregt, T. Rutkens, D. Bergsma (ATHENA), F. Ebeling, M. Bucht, (Frankfurt), O. Chokoshvili, E. Karkashadze (IDACIRC), E. Fontas, K. Dollet, C. Caissotti (NICE, HIV cohort), J. Fanti, A. Tavelli, A. Rodanò (ICoNA), V. Borghi (Modena), A.Bruguera, J. Reyes-Urueña, A. Montoliu (PISCIS), H. Bucher, A. Scherrer, J. Schuhmacher, A. Traytel (SHCS), V. Svedhem-Johansson, L. Mattsson, K. Alenadaf, (Swedish InfCare), F. Lampe, C. Chaloner (Royal Free, HIV cohort), A. Lazzarin, A. Poli, S. Nozza (St. Rafael, Milano), K. Mohrmann, J. Rockstroh (Bonn, HIV cohort), G. Fätkenheuer, N. Schulze, B. Frank, M. Stecher and H. Weiler (Cologne HIV cohort).

RESPOND Scientific Steering committee: J. Lundgren (co-chair), H. Günthard (Co-Chair), C. Mussini, R. Zangerle, A. Sönnnerborg, V. Vannappagari, J.C. Wasmuth, M. Law, F. Wit, R. Haubrich, H. Bucher, C. Pradier, H. Garges, C. Necsoi, G. Wandeler, C. Smith, J.J. Vehreschild, F. Rogatto, C. Stephan, N. Chkhartishvili, A. d'Arminio Monforte, A. Bruguera and A. Castagna.

RESPOND Executive committee:

Mocroft (Chair), J. Lundgren, R. Zangerle, H. Günthard, G. Wandeler, M. Law, F. Rogatto, C. Smith, V. Vannappagari and S. De Wit.

RESPOND coordination office, date management and quality assurance:

B. Neesgaard, J.F. Larsen, A. Bojesen, M.L. Jacobsen, T. Bruun, E. Hansen, D. Kristensen, T. Elsing, S. Thomsen T. Weide and P. Iversen.

Scientific interest group moderators:

L. Ryom, A. Mocroft (Outcomes with antiretroviral treatment), L. Peters, J. Rockstroh (Hepatitis), D. Raben and J. Kowalska (Public Health), O. Kirk, A. Philips, V. Cambiano and Jens Lundgren (PrEP)

Members of the scientific interest group:

Hepatis, **Public Health**, Outcomes with antiretroviral treatment, PrEP, Resistance

<https://www.chip.dk/Studies/RESPOND/Scientific-Interest-Groups/Public-Health>

Statisticians:

A. Mocroft and L. Greenberg

Funding:

The International Cohort Consortium of Infectious Disease (RESPOND) has received funding from ViiV Healthcare LLC and Gilead Sciences. Additional support has been provided by participating cohorts contributing data in-kind: Austrian HIV Cohort Study (AHIVCOS), The Australian HIV Observational Database (AHOD), CHU Saint-Pierre, University Hospital Cologne, The EuroSIDA cohort, Frankfurt HIV Cohort Study, Georgian National AIDS Health Information System (AIDS HIS), Modena HIV Cohort, San Raffaele Scientific Institute, Swiss HIV Cohort Study (SHCS), Royal Free HIV Cohort Study.